Trial Profile
An Open-Label, Multicenter Phase 2 Study of E7080/ LENVIMA (Lenvatinib Mesylate) in Subjects With Unresectable Biliary Tract Cancer Who Failed Gemcitabine-based Combination Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary)
- Indications Adenocarcinoma; Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
- Sponsors Eisai Co Ltd
- 02 Apr 2019 Status changed from active, no longer recruiting to completed.
- 27 Mar 2019 Planned End Date changed from 1 Apr 2019 to 1 Mar 2019.
- 27 Mar 2019 Planned primary completion date changed from 1 Apr 2019 to 1 Mar 2019.